The purpose of this study is to see how effective Plozasiran is at reducing triglyceride levels in people with severe hypertriglyceridemia. Participants in the study will receive either Plozasiran or a placebo and will be monitored over a period of 12 months. During this time, the study will measure changes in triglyceride levels and monitor for any side effects. The goal is to determine if Plozasiran can significantly lower triglyceride levels compared to the placebo.

Participants will receive regular injections and attend scheduled visits to track their progress. The study aims to provide valuable information on the safety and effectiveness of Plozasiran, which could lead to new treatment options for people with severe hypertriglyceridemia. This research is important for understanding how to better manage this condition and improve patient outcomes.

The purpose of this study is to assess how effective and safe Plozasiran is in reducing fasting triglyceride levels in adults with severe hypertriglyceridemia. Participants in the study will receive either Plozasiran or a placebo, which is a substance with no active medication. The study will last for about 12 months, during which participants will receive regular injections and have their triglyceride levels monitored at various points to see how they change over time.

Throughout the study, participants will be closely monitored for any changes in their health and any side effects they might experience. The goal is to determine if Plozasiran can significantly lower triglyceride levels compared to the placebo, and to see if it helps more participants reach healthier triglyceride levels. This research could lead to a new treatment option for people with severe hypertriglyceridemia, potentially improving their health and reducing the risk of complications associated with high triglyceride levels.

The research will evaluate the effectiveness and safety of Plozasiran compared to placebo in people who have experienced at least two episodes of acute pancreatitis in the past. The medication will be given as a subcutaneous injection, which means it is injected under the skin using a pre-filled syringe. The study medication or placebo will be administered over a period of 48 months.

During the study, researchers will monitor how the treatment affects triglyceride levels in the blood and how well it prevents new episodes of acute pancreatitis. They will also track how the treatment impacts participants’ daily activities and overall health status. The medication being tested, Plozasiran, is designed to reduce the production of a protein called Apolipoprotein C-III, which plays a role in controlling triglyceride levels in the body.

The purpose of the study is to evaluate how safe plozasiran is for long-term use in people with hypertriglyceridemia. Participants in the study will receive injections of plozasiran and will be monitored over time to see how their triglyceride levels change. The study will also look at other factors, such as changes in cholesterol levels and any side effects that may occur during the treatment period.

Throughout the study, participants will have regular check-ups to track their health and any changes in their condition. The study aims to provide valuable information on the safety and potential benefits of plozasiran for managing high triglyceride levels in the long term. This research could help improve treatment options for individuals with hypertriglyceridemia.

The purpose of the study is to assess how effective and safe Plozasiran is in reducing fasting triglyceride levels in adults with Hypertriglyceridemia. Participants in the study will receive either the Plozasiran injection or a placebo. The study will last for about 12 months, during which participants will have regular check-ups to monitor their triglyceride levels and overall health.

This study is conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure the results are unbiased. The main goal is to see if Plozasiran can significantly lower triglyceride levels compared to the placebo, and to determine how many participants achieve a healthy triglyceride level by the end of the study.

During the trial, participants will receive four weekly doses of A24110He. Some participants will receive a placebo instead. The trial will monitor participants’ health through regular check-ups, including physical exams and tests to measure vital signs like blood pressure and heart rate. Blood tests will also be conducted to check various health markers, such as kidney and liver function, blood sugar levels, and other important indicators.

The trial will also measure the levels of A24110He in the blood to understand how the body processes the treatment. This includes determining the highest concentration of the treatment in the blood and how long it stays in the body. The study is expected to provide valuable information about the safety and potential benefits of A24110He for people with type 2 diabetes and high triglycerides.

Participants in the study will receive either Olezarsen or a placebo through subcutaneous injection, which means the injection is given under the skin. The study will last for about 53 weeks, during which the changes in fasting triglyceride levels will be monitored. Fasting triglyceride levels refer to the amount of triglycerides in the blood after a period without eating. The study will also look at other health markers and events, such as changes in cholesterol levels and the occurrence of pancreatitis, which is inflammation of the pancreas, and major cardiovascular events like heart attacks or strokes.

The safety and tolerability of Olezarsen will be assessed by comparing it to the placebo. This includes monitoring for any adverse events, changes in vital signs, and results from physical exams and laboratory tests. The goal is to determine if Olezarsen is effective and safe for reducing triglyceride levels in patients with these conditions.

The purpose of this study is to evaluate the safety and tolerability of Olezarsen in patients with Severe Hypertriglyceridemia. Participants in the study will receive regular injections of the medication over a period of time. The study will monitor participants for any changes in their health, including laboratory values and any side effects they may experience. The study will also track the use of any additional medications that participants may need during the trial.

Participants will be involved in the study for a period of up to 66 weeks. During this time, they will receive injections and attend regular check-ups to monitor their health and the effects of the treatment. The study aims to provide valuable information on how well Olezarsen is tolerated by patients and its impact on Severe Hypertriglyceridemia.

In addition to Pegozafermin, the study involves the use of Simvastatin, a medication commonly used to lower cholesterol levels. Simvastatin will be provided in the form of film-coated tablets. Participants will continue their usual lipid-modifying therapy, which helps manage cholesterol levels, throughout the study. The study will last for a total of 52 weeks, with the main focus on changes in triglyceride levels at the 26-week mark.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study will also look at changes in other cholesterol levels, such as non-high-density lipoprotein cholesterol (non-HDL-C) and high-density lipoprotein cholesterol (HDL-C), as well as liver fat content using MRI scans. The goal is to gather information on the safety and effectiveness of Pegozafermin in managing Severe Hypertriglyceridemia.